Universal MRSA screening: Is it worth the cost?

Even though many consider universal screening for methicillin-resistant Staphylococcus aureus infections as a best practice for preventing the spread of the antibiotic-resistant infection, screening every patient for MRSA may be too costly for many hospitals, according to two abstracts set to be presented at IDWeek.

Advertisement

Researchers looked at the cost of a program in which staff test all patients for MRSA and then isolate carriers. They found such a program that tested patients for MRSA in the nose would cost a hospital $103,000 per 10,000 hospital admissions while preventing nearly three MRSA infections.

The cost of a program that targeted only high-risk patients also outweighed potential savings from preventing infections, the researchers found. Nares testing prevented fewer than one infection per 1,000 high-risk admissions and created a loss of $36,899.

“Although more extensive MRSA testing and isolation could prevent hospital-acquired MRSA infections, we found the cost of such a program far exceeds any savings to the hospital,” said James McKinnell, MD, a Los Angeles Biomedical Research Institute lead researcher. “Our results are surprising because we know that preventing MRSA infections is better for the healthcare system as a whole, but the rewards of this effort do not seem to come back to the hospital in a meaningful way. In today’s constrained healthcare environment, hospitals must either be given better financial incentives or better and more cost-effective infection prevention strategies to provide the greatest benefit to the people they serve.”

More articles on MRSA:

Shark skin-inspired surface limits MRSA spread, study shows
Viewpoint: Are current hospital MRSA control policies effective enough?
MRSA colonization not limited to nose: Study

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.